Health
SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data In vitro analysis of the SeaStar Medical SCD indicates modulation of the immune response, shifting monocytes towards an anti-inflammatory, reparative phenotype SeaStar Medical hosts an industry symposium and panel discussion focused on innovation in the treatment of pediatric AKI, supporting its emerging leadership in this community DENVER, March 30,
About this update from Seastar Medical Holding Corporation
[{"type":"image","alt":"SeaStar Medical","displaySize":"","headline":null,"caption":"SeaStar Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/4c7240b3e0b5bc01bb2108fbeef0b4c6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a2PlyGYjCebNG9cYp9_P4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NA--/https://media.zenfs.com/en/globenewswire.com/4c7240b3e0b5bc01bb2108fbeef0b4c6","width":300,"height":110}},"lazy":false},{"type":"text","content":"Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data ","length":147,"tagName":"p"},{"type":"text","content":"In vitro analysis of the SeaStar Medical SCD indicates modulation of the immune response, shifting monocytes towards an anti-inflammatory, reparative phenotype ","length":159,"tagName":"p"},{"type":"text","content":"SeaStar Medical hosts an industry symposium and panel discussion focused on innovation in the treatment of pediatric AKI, supporting its emerging leadership in this community","length":174,"tagName":"p"},{"type":"text","content":"DENVER, March 30, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today the presentations of new SAVE Registry data and investigator led research on the mechanism of action of the Selective Cytopheretic Device (SCD) therapy at the 31st International Conference on Advances in Critical Care Nephrology, also known as AKI & CRRT 2026.","length":523,"tagName":"p"},{"type":"text","content":"SeaStar Medical highlights two poster presentations that were presented at the meeting, including new expanded real-world data from the treatment of pediatric patients from the SAVE Registry, as well as investigator led gene expression research on the immunomodulatory effects of the Company’s SCD therapy.","length":306,"tagName":"p"},{"type":"text","content":"SeaStar Medical has also assembled leading experts in the treatment of pediatric Acute Kidney Injury (AKI) to speak at its educational symposium to discuss the complex pathophysiology of the condition, the QUELIMMUNE SAVE Registry, the immunomodulatory effects...